<DOC>
	<DOCNO>NCT00972517</DOCNO>
	<brief_summary>The objective study evaluate immunogenicity safety GSK Biologicals ' investigational vaccine GSK2340272A child age 3 17 year .</brief_summary>
	<brief_title>Study Evaluate Immunogenicity Safety Investigational Influenza Vaccine ( H1N1 ) Children</brief_title>
	<detailed_description>This Protocol Posting update follow Protocol amendment 1 , October 2009 . The impacted section study design section , outcomes measure section intervention section .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) ( LAR ) comply requirement protocol . Children , male female , age 3 17 year time first study vaccination . Written inform consent obtain subject parent ( ) LAR ( ) subject . Assent obtain subject applicable . Healthy child establish medical history clinical examination enter study . Parent/LAR access consistent mean telephone contact , land line mobile , NOT pay phone multipleuser device . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine plan use study period . Clinically virologically confirm influenza infection within six month precede study start . Planned administration vaccine 30 day prior 30 day study vaccine administration . Chronic administration immunosuppressant immunemodifying drug within three month prior enrolment study plan administration study period . Acute disease and/or fever time enrolment Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination . Acute chronic , clinicallysignificant pulmonary , cardiovascular , hepatic renal functional abnormality , determine medical history physical examination . Previous administration H1N1 A/Californialike vaccine . Administration immunoglobulins and/or blood product within three month prior enrolment study , plan study . If subject female childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution two month completion vaccination series . Any known suspect allergy constituent influenza vaccine ; history anaphylactictype reaction constituent influenza vaccine ; history severe adverse reaction previous influenza vaccine . Known use analgesic antipyretic medication within 12 hour prior first vaccination . Child Care .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>GSK Bio 's influenza vaccine GSK2340272A</keyword>
	<keyword>influenza infection</keyword>
</DOC>